We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Helps Patients with Risk of Heart Disease

By LabMedica International staff writers
Posted on 28 Mar 2013
A simple screening blood test and management program can be effective in preventing heart failure for at-risk patients.

Blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart is functioning and elevated BNP levels can indicate established heart failure.

Cardiologists at St. More...
Vincent's University Hospital (Dublin, Ireland) recruited 1,374 patients from 39 family practices as part of a five-year study. The participants were asymptomatic patients over 40 years of age with risk factors for heart failure and randomized into an intervention and a control group. Patients in the intervention group were screened for blood levels of BNP, at least annually and all patients were screened for cardiovascular risk factors.

Of the patients in the intervention group, 41.6% showed elevated BNP levels at some point during the study. These patients received an echocardiogram and continued care under both their physicians and a specialist cardiology service. In addition to showing lower rates of the primary endpoint, intervention patients also had lower rates of emergency hospitalization for major cardiovascular events at 22.3 per 1,000 patient years compared to 40.4 per 1,000 patient years in the control group. The investigators found that a significantly lower number of patients in the intervention group than in the control group met the primary endpoint of new onset heart failure requiring hospitalization or left ventricular dysfunction.

Kenneth McDonald, MD, director of the Heart Failure Unit at St. Vincent's and a senior author of the study, said "Our study shows that a simple blood test screening, followed by targeted care of people at heightened risk of heart failure, can result in a dramatic reduction in cardiovascular events. This is good news, since heart failure has become a major public health problem and middle-aged adults today have a 20% to 30% lifetime risk of developing heart failure." The study was presented at the American College of Cardiology's 62nd Annual Scientific Session held March 9–11, 2013, in San Francisco (CA, USA).

Related Links:
St. Vincent's University Hospital



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.